BioCentury | Sep 26, 2005
Analyst Picks & Changes

Analyst picks & changes

...key driver for the stock. The TLR9 agonist is partnered with Pfizer (PFE). Curis (CRIS) America's Growth Capital...
BioCentury | Sep 12, 2005
Analyst Picks & Changes

Analyst picks & changes

...CRTX submitted an sNDA in March which covered a change in manufacturing sites. CuraGen (CRGN) America's Growth Capital...
BioCentury | Aug 1, 2005
Analyst Picks & Changes

Analyst picks & changes

...sales of $4M, which beat his estimate by $1.2M (see "EPS Watch," A19). Sangamo (SGMO) America's Growth Capital...
BioCentury | Jun 27, 2005
Analyst Picks & Changes

Analyst picks & changes

...and to $1.31B from $1.28B. Vivitrex is an injectable extended-release naltrexone (see B2). Dyax (DYAX) America's Growth Capital...
BioCentury | May 16, 2005
Finance

Analyst picks & changes

...Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/13 cls ArQule (ARQL) America's Growth Capital...
...of the cardiovascular and cancer company because Rodman reorganized its research coverage. OxiGene (OXGN; SSE:OXGN) America's Growth Capital...
Items per page:
1 - 5 of 5
BioCentury | Sep 26, 2005
Analyst Picks & Changes

Analyst picks & changes

...key driver for the stock. The TLR9 agonist is partnered with Pfizer (PFE). Curis (CRIS) America's Growth Capital...
BioCentury | Sep 12, 2005
Analyst Picks & Changes

Analyst picks & changes

...CRTX submitted an sNDA in March which covered a change in manufacturing sites. CuraGen (CRGN) America's Growth Capital...
BioCentury | Aug 1, 2005
Analyst Picks & Changes

Analyst picks & changes

...sales of $4M, which beat his estimate by $1.2M (see "EPS Watch," A19). Sangamo (SGMO) America's Growth Capital...
BioCentury | Jun 27, 2005
Analyst Picks & Changes

Analyst picks & changes

...and to $1.31B from $1.28B. Vivitrex is an injectable extended-release naltrexone (see B2). Dyax (DYAX) America's Growth Capital...
BioCentury | May 16, 2005
Finance

Analyst picks & changes

...Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/13 cls ArQule (ARQL) America's Growth Capital...
...of the cardiovascular and cancer company because Rodman reorganized its research coverage. OxiGene (OXGN; SSE:OXGN) America's Growth Capital...
Items per page:
1 - 5 of 5